insights_auto
Why is 22UA down ၂.၄၂%?
Dive Deeperchevron_right
22UA:ETR
BioNTech SE - ADR
၇၈.၆၀ €
arrow_downward
-၂.၄၂%(-၁.၉၅) 1D
အောက် ၁၆, GMT+၂ ၁၇:၃၅:၅၁ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
၈၀.၇၅ €
High
၈၁.၁၅ €
Low
၇၈.၄၀ €
Mkt. cap
ဋေ ၂.၂၀ ထ
Avg. vol.
၂.၆၄ သောင်း
Volume
၁.၂၉ သောင်း
52-wk high
၁၀၅.၇၀ €
52-wk low
၆၈.၃၀ €
No. of employees
၈ ထောင်
Open
၈၀.၇၅ €
High
၈၁.၁၅ €
Low
၇၈.၄၀ €
Mkt. cap
ဋေ ၂.၂၀ ထ
Avg. vol.
၂.၆၄ သောင်း
Volume
၁.၂၉ သောင်း
52-wk high
၁၀၅.၇၀ €
52-wk low
၆၈.၃၀ €
No. of employees
၈ ထောင်
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁ နာရီ
BioNTech's BNT113 Readout Now Hinges on Overall Survival as Shares Test 52-Week Floor
24/7 Wall St.
·
ပြီးခဲ့သည့် ၂၀ နာရီ
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Pluang
·
ပြီးခဲ့သည့် ၂ ရက်
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
ပြီးခဲ့သည့် ၃ ရက်
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR